Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with P
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q3 2025 | PEG-8 LAURATE | TOPICAL | SUSPENSION | 0.63 %w/w | Correction | ||
| Q4 2025 | PEG-8 LAURATE | TOPICAL | SUSPENSION | 0.63 %w/v | Correction | ||
| Q3 2025 | POLOXAMER 188 | ORAL | TABLET, FILM COATED | 93mg | Correction | ||
| Q4 2025 | POLOXAMER 188 | ORAL | TABLET, FILM COATED | 3mg | Correction | ||
| Q3 2025 | PROPYLPARABEN SODIUM | ORAL | CAPSULE | 1mg | Correction | ||
| Q3 2025 | PROPYLPARABEN SODIUM | ORAL | POWDER, FOR SUSPENSION | 16mg | Correction | ||
| Q3 2025 | PROPYLPARABEN SODIUM | ORAL | SOLUTION | 30mg | Correction | ||
| Q3 2025 | PROPYLPARABEN SODIUM | ORAL | SUSPENSION | 4mg | Correction | ||
| Q3 2025 | PROPYLPARABEN SODIUM | ORAL | TABLET | 0.06 mg | Correction | ||
| Q3 2025 | PROPYLPARABEN SODIUM | ORAL | TABLET, ORALLY DISINTEGRATING | 0.10 mg | Correction | ||
| Q3 2025 | PALMITIC ACID | INTRAVENOUS | INJECTION, SUSPENSION | NA | Deletion | ||
| Q3 2025 | PEANUT OIL | TOPICAL | CREAM, AUGMENTED | 10.00 %w/w | Deletion | ||
| Q3 2025 | PHOSPHOLIPID | INTRAVENOUS | INJECTION, EMULSION | 120.00 mg | Deletion | ||
| Q3 2025 | POLOXAMER 407 | ORAL | TABLET, FILM COATED | 106.70 mg | Deletion | ||
| Q3 2025 | POLYETHYLENE GLYCOL 3350 | NASAL | SOLUTION | 40000.00 mg/ 100.00 ml | Deletion | ||
| Q3 2025 | POLYETHYLENE GLYCOL 3350 | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 8.50 mg | Deletion | ||
| Q3 2025 | POLYETHYLENE GLYCOL 4000 | INTRAVENOUS | INJECTION, SUSPENSION | 0.49 %w/v | Deletion | ||
| Q3 2025 | POLYETHYLENE GLYCOL 4000 | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 1.80 mg | 2mg | Deletion | |
| Q3 2025 | POLYETHYLENE GLYCOL 6000 | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 0.50 mg | Deletion | ||
| Q3 2025 | POLYOXYL 40 HYDROGENATED CASTOR OIL | ORAL | LIQUID | 10.20 mg/ 1.00 ml | 102mg | Deletion | |
| Q3 2025 | POVIDONE | ORAL | POWDER, FOR SOLUTION | 4.50 mg | Deletion | ||
| Q3 2025 | POVIDONE K25 | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 5.35 mg | 11mg | Deletion | |
| Q3 2025 | POVIDONE K30 | ORAL | LIQUID | 30.00 mg/ 1.00 ml | 300mg | Deletion | |
| Q3 2025 | PROPYL GALLATE | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 0.04 mg | Deletion | ||
| Q3 2025 | PROPYLENE GLYCOL | NASAL | SOLUTION | 12000.00 mg/ 100.00 ml | Deletion | ||
| Q3 2025 | PROPYLPARABEN | URETHRAL | JELLY | 0.03 %w/v | Deletion | ||
| Q3 2025 | PEG-40 SORBITAN DIISOSTEARATE | ORAL | LIQUID | 100.00 mg/ 15.00 ml | MDE Replacement | ||
| Q4 2025 | PEG-40 SORBITAN DIISOSTEARATE | ORAL | LIQUID | 20mg | MDE Replacement | ||
| Q3 2025 | POLYCARBOPHIL | OPHTHALMIC | GEL | 0.38 %w/w | MDE Replacement | ||
| Q4 2025 | POLYCARBOPHIL | OPHTHALMIC | GEL | 1mg | MDE Replacement | ||
| Q3 2025 | POLYETHYLENE GLYCOL 300 | INTRAMUSCULAR | INJECTION | 50.00 %v/v | MDE Replacement | ||
| Q4 2025 | POLYETHYLENE GLYCOL 300 | INTRAMUSCULAR | INJECTION | 16875mg | MDE Replacement | ||
| Q3 2025 | POLYSORBATE 80 | OPHTHALMIC | SOLUTION | 0.25 %w/v | MDE Replacement | ||
| Q4 2025 | POLYSORBATE 80 | OPHTHALMIC | SOLUTION | 8mg | MDE Replacement | ||
| Q3 2025 | POLYSORBATE 80 | ORAL | TABLET, CHEWABLE | 0.02 mg | MDE Replacement | ||
| Q4 2025 | POLYSORBATE 80 | ORAL | TABLET, CHEWABLE | 84mg | MDE Replacement | ||
| Q3 2025 | PROPYLENE GLYCOL | ORAL | CAPSULE, EXTENDED RELEASE | 14.60 mg | MDE Replacement | ||
| Q4 2025 | PROPYLENE GLYCOL | ORAL | CAPSULE, EXTENDED RELEASE | 8mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Bioequivalence
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: September 19, 2025
Database Last Updated: October 22, 2025